WorldHeart Receives Unconditional BTT Study Approval for Levacor VAD

World Heart Corporation, a developer of mechanical circulatory systems, announced Monday that it has received unconditional approval from the U.S. Food and Drug Administration for the bridge-to-transplant study of the Levacor Ventricular Assist Device (VAD).
Utah Pulse